联合免疫检查点抑制剂治疗非小细胞肺癌  

Combinational immunological checkpoint inhibitors for non-small cell lung cancer

作　　者：原颖丽 马克威[1] 

机构地区：[1]吉林大学第一医院肿瘤中心,长春130021

出　　处：《国际肿瘤学杂志》2017年第12期933-936,共4页Journal of International Oncology

摘　　要：免疫检查点抑制剂已经成为晚期非小细胞肺癌（NSCLC）患者的主要治疗方案之一。尽管在不同疾病环境中NSCLC患者表现出对标准方案化疗的优越性，但在对化疗耐受及存在基因突变的高分子选择的患者中，反应率仍较低，这与已知有限的生物标志物、肿瘤微环境的复杂和动态性有关。研究肿瘤细胞逃避免疫系统所采用的方法不同，为新型组合策略奠定了基础。联合治疗不仅使治疗的疗效得到提高，而且使客观缓解率得到明显改善。Immunological checkpoint inhibitors have become one of the major treatment options for patients with advanced non-small cell lung cancer （NSCLC）. Despite patients with NSCLC show the superiority of standard chemotherapy in different disease settings, the response rate is still low in patients with high macromolecule selection for chemotherapy tolerance and gene mutation. This is related to the complexity and dynamics of known limited biomarkers and tumor microenvironment. Different methods of tumor cells to evade the immune system used to lay the foundation for the new combination strategy. Combination therapy not only improves the efficacy of treatment, but also makes the objective response rate improved significantly.

关 键 词：癌 非小细胞肺 免疫抑制剂 治疗 

分 类 号：R734.2[医药卫生—肿瘤]